Literature DB >> 33493163

Development of a porcine model of phenylketonuria with a humanized R408W mutation for gene editing.

Robert A Kaiser1,2, Daniel F Carlson3, Kari L Allen1, Dennis A Webster3, Caitlin J VanLith1, Clara T Nicolas1,4, Lori G Hillin1, Yue Yu1, Catherine W Kaiser1, William R Wahoff1, Raymond D Hickey1,5, Adrienne L Watson3, Shelley R Winn6, Beat Thöny7, Douglas R Kern3, Cary O Harding6, Joseph B Lillegard1,2,8.   

Abstract

Phenylketonuria (PKU) is a metabolic disorder whereby phenylalanine metabolism is deficient due to allelic variations in the gene for phenylalanine hydroxylase (PAH). There is no cure for PKU other than orthotopic liver transplantation, and the standard of care for patients is limited to dietary restrictions and key amino acid supplementation. Therefore, Pah was edited in pig fibroblasts for the generation of PKU clone piglets that harbor a common and severe human mutation, R408W. Additionally, the proximal region to the mutation was further humanized by introducing 5 single nucleotide polymorphisms (SNPs) to allow for development of gene editing machinery that could be translated directly from the pig model to human PKU patients that harbor at least one classic R408W allele. Resulting piglets were hypopigmented (a single Ossabaw piglet) and had low birthweight (all piglets). The piglets had similar levels of PAH expression, but no detectable enzymatic activity, consistent with the human phenotype. The piglets were fragile and required extensive neonatal care to prevent failure to thrive and early demise. Phenylalanine levels rose sharply when dietary Phe was unrestricted but could be rapidly reduced with a low Phe diet. Fibroblasts isolated from R408W piglets show susceptibility to correction using CRISPR or TALEN, with subsequent homology-directed recombination to correct Pah. This pig model of PKU provides a powerful new tool for development of all classes of therapeutic candidates to treat or cure PKU, as well as unique value for proof-of-concept studies for in vivo human gene editing platforms in the context of this humanized PKU allele.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33493163      PMCID: PMC7833140          DOI: 10.1371/journal.pone.0245831

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  33 in total

1.  Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria.

Authors:  Kelly Hamman; Heather Clark; Eugenio Montini; Muhsen Al-Dhalimy; Markus Grompe; Milton Finegold; Cary O Harding
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 2.  The phenylalanine hydroxylating system.

Authors:  S Kaufman
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1993

3.  Dwarfism and low insulin-like growth factor-1 due to dopamine depletion in Pts-/- mice rescued by feeding neurotransmitter precursors and H4-biopterin.

Authors:  Lina Elzaouk; Walter Leimbacher; Matteo Turri; Birgit Ledermann; Kurt Burki; Nenad Blau; Beat Thony
Journal:  J Biol Chem       Date:  2003-05-06       Impact factor: 5.157

Review 4.  Phenylketonuria: screening, treatment and maternal PKU.

Authors:  R Matalon; K Michals
Journal:  Clin Biochem       Date:  1991-08       Impact factor: 3.281

5.  Recurrence of the R408W mutation in the phenylalanine hydroxylase locus in Europeans.

Authors:  R C Eisensmith; A A Goltsov; C O'Neill; L A Tyfield; E I Schwartz; A I Kuzmin; S S Baranovskaya; G L Tsukerman; E Treacy; C R Scriver
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

6.  Mouse models of human phenylketonuria.

Authors:  A Shedlovsky; J D McDonald; D Symula; W F Dove
Journal:  Genetics       Date:  1993-08       Impact factor: 4.562

7.  Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Ming Ying; Aurora Martinez; Sydney Weber; Jacob Raber; Cary O Harding
Journal:  Mol Genet Metab       Date:  2017-10-19       Impact factor: 4.797

Review 8.  The PAH gene, phenylketonuria, and a paradigm shift.

Authors:  Charles R Scriver
Journal:  Hum Mutat       Date:  2007-09       Impact factor: 4.878

9.  Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes.

Authors:  Ashley M Jacobi; Garrett R Rettig; Rolf Turk; Michael A Collingwood; Sarah A Zeiner; Rolen M Quadros; Donald W Harms; Paul J Bonthuis; Christopher Gregg; Masato Ohtsuka; Channabasavaiah B Gurumurthy; Mark A Behlke
Journal:  Methods       Date:  2017-03-27       Impact factor: 3.608

10.  Ossabaw Pigs With a PCSK9 Gain-of-Function Mutation Develop Accelerated Coronary Atherosclerotic Lesions: A Novel Model for Preclinical Studies.

Authors:  Fang Yuan; Liang Guo; Kyoung-Ha Park; John R Woollard; Kwon Taek-Geun; Kai Jiang; Tamene Melkamu; Bin Zang; Samantha L Smith; Scott C Fahrenkrug; Frank D Kolodgie; Amir Lerman; Renu Virmani; Lilach O Lerman; Daniel F Carlson
Journal:  J Am Heart Assoc       Date:  2018-03-23       Impact factor: 5.501

View more
  3 in total

Review 1.  Phenylketonuria.

Authors:  Francjan J van Spronsen; Nenad Blau; Cary Harding; Alberto Burlina; Nicola Longo; Annet M Bosch
Journal:  Nat Rev Dis Primers       Date:  2021-05-20       Impact factor: 52.329

Review 2.  The Utility of Genomic Testing for Hyperphenylalaninemia.

Authors:  Elisabetta Anna Tendi; Maria Guarnaccia; Giovanna Morello; Sebastiano Cavallaro
Journal:  J Clin Med       Date:  2022-02-18       Impact factor: 4.964

Review 3.  Novel Gene-Correction-Based Therapeutic Modalities for Monogenic Liver Disorders.

Authors:  Mahsa Ghasemzad; Mahdieh Hashemi; Zohre Miri Lavasani; Nikoo Hossein-Khannazer; Haleh Bakhshandeh; Roberto Gramignoli; Hani Keshavarz Alikhani; Mustapha Najimi; Saman Nikeghbalian; Massoud Vosough
Journal:  Bioengineering (Basel)       Date:  2022-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.